Currently out of the existing stock ratings of David Amsellem, 428 are a BUY (75.22%), 127 are a HOLD (22.32%), 14 are a SELL (2.46%).

David Amsellem

Work Performance Price Targets & Ratings Chart

Analyst David Amsellem, currently employed at PIPER SANDLER, carries an average stock price target met ratio of 55.44% that have a potential upside of 28.36% achieved within 239 days.

David Amsellem’s has documented 1,124 price targets and ratings displayed on 55 stocks. The coverage is on Healthcare, Consumer Defensive, Financial Services sectors.

Most recent stock forecast was given on AXSM, Axsome Therapeutics at 18-Sep-2026.

Wall Street Analyst David Amsellem

Analyst best performing recommendations are on RVNC (REVANCE THE).
The best stock recommendation documented was for RVNC (REVANCE THE) at 8/9/2024. The price target of $6 was fulfilled within 3 days with a profit of $2.47 (69.97%) receiving and performance score of 233.24.

Average potential price target upside

of $70.28 (47.61%) on OPTN (OPTINOSE).
of $61.33 (20.88%) on AMGN (AMGEN).
of $57.85 (27.44%) on ABBV (ABBVIE).

ADMS Adamas Pharmaceuticals AGN Allergan plc AKRX Akorn AMPH Amphastar P AMRX Amneal Pharmaceuticals ATRS Antares Pharma BDSI BioDelivery Sciences International BHC Bausch Health Companies COLL Collegium Pharmaceutical EGRX Eagle Pharmaceuticals ENDP Endo International PLC HZNP Horizon Pharma PLC INSY INSYS Therapeutics JAZZ Jazz Pharmaceuticals PLC MNK Mallinckrodt plc NBIX Neurocrine Biosciences PCRX Pacira Pharmaceuticals RVNC Revance The SUPN Supernus Pharmaceuticals TEVA Teva Pharma Industries Ltd ADR CARA Cara Therapeutic EVFM Evofem Biosciences OGN Organon OPTN OptiNose REPH Recro Pharma ASRT Assertio Therapeutics VTRS Viatris ALKS Alkermes Plc AVDL Avadel Pharmaceuticals PLC BXRX Baudax Bio HRMY Harmony Biosciences Holdings NOVN Novan XERS Xeris Pharmaceuticals AXSM Axsome Therapeutics CERE Cerevel Therapeutics Holdings CORT Corcept Therapeutics IRWD Ironwood Pharmaceuticals AMGN Amgen ITCI Intracellular Th INDV Indivior PLC BIIB Biogen MDCO The Medicines Company MYL Viatris SAGE Sage Therapeutic SGNT Sagent Pharmaceuticals AQST Aquestive Therapeutics BMY Bristol-Myers Squibb Company ABBV AbbVie ACT Enact Holdings ADM Archer-Daniels-Midland Company AVD American Vanguard BX Blackstone Group EG Everest Group Ltd ESPR Esperion Therapeutics FENC Fennec Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Carl Byrnes (NORTHLAND CAPITAL MARKETS)

Buy Since 29-Nov-2017

$8.5

$0.28 (3.41%)

4 years 11 months 4 days ago
(18-Nov-2021)

0/3 (0%)

$0.33 (4.04%)

Please subscribe to see extended stock data

Raghuram Selvaraju (HC WAINWRIGHT)

Hold Since 13-Oct-2021

$-0.22 (-2.68%)

$10

5 years 9 days ago
(13-Oct-2021)

1/7 (14.29%)

$-0.07 (-0.87%)

Please subscribe to see extended stock data

David Amsellem (PIPER SANDLER)

Buy Since 12-Jan-2016

$-0.22 (-2.68%)

5 years 9 days ago
(13-Oct-2021)

4/5 (80%)

$-0.07 (-0.87%)

Please subscribe to see extended stock data

Jason Butler (JMP)

Buy Since 17-Aug-2017

$14

5 years 9 days ago
(13-Oct-2021)

3/7 (42.86%)

$9.25 (194.74%)

Please subscribe to see extended stock data

Tim Lugo (WILLIAM BLAIR)

Buy Since 05-May-2014

5 years 10 days ago
(12-Oct-2021)

2/2 (100%)

$11.15 (36.14%)

586

Please subscribe to see extended stock data

Show more analysts

Please expand the browser size to see the chart

Which stock is David Amsellem most bullish on?

Potential upside of $100.86 has been obtained for AXSM (AXSOME THERAPEUTICS)

Which stock is David Amsellem most reserved on?

Potential downside of -$5.87 has been obtained for AMPH (AMPHASTAR P)

What Year was the first public recommendation made by David Amsellem?

On 2009